Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
55 hedge funds and large institutions have $379M invested in Inozyme Pharma in 2021 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 21 increasing their positions, 11 reducing their positions, and 5 closing their positions.
91% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 11
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3.12% more ownership
Funds ownership: 78.57% → 81.69% (+3.1%)
2% more funds holding
Funds holding: 54 → 55 (+1)
0% more capital invested
Capital invested by funds: $379M → $379M (+$398K)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$18M |
| 2 |
BlackRock
New York
|
+$5.1M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.26M |
| 4 |
CCM
CAAS Capital Management
New York
|
+$3.92M |
| 5 |
Millennium Management
New York
|
+$3.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$13.2M |
| 2 |
O
OrbiMed
New York
|
-$8.26M |
| 3 |
YU
Yale University
New Haven,
Connecticut
|
-$2.34M |
| 4 |
CA
CHI Advisors
New York
|
-$1.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$268K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
51
Ameritas Investment Partners
Lincoln,
Nebraska
| $14K | – | – | – |
|
|
PCM
52
Penserra Capital Management
Orinda,
California
| $10K | -$110 | -5 | -0.9% |
|
53
Bank of Montreal
Toronto,
Ontario, Canada
| $7K | -$19.4K | -877 | -69% |
|
54
Daiwa Securities Group
Tokyo,
Japan
| $1K | – | – | – |
|
|
AIG
55
American International Group
New York
| $139 | +$50.5K | +2,287 | +48% |
|
|
O
56
OrbiMed
New York
| – | -$8.26M | -400,400 | Closed |
|
|
YU
57
Yale University
New Haven,
Connecticut
| – | -$2.34M | -113,502 | Closed |
|
58
D.E. Shaw & Co
New York
| – | -$248K | -12,016 | Closed |
|
|
APM
59
Avidity Partners Management
Dallas,
Texas
| – | -$200K | -9,683 | Closed |
|
|
RFA
60
Reilly Financial Advisors
La Mesa,
California
| – | -$2K | -100 | Closed |
|
INZY Hedge Fund Activity: Q1 2021 in Review
55 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q1 2021, worth a combined $379M — up 0.11% from $379M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new INZY positions and 5 closed out — a net gain of 1 holder — while 21 added to existing stakes and 11 trimmed.
The largest buyer was Deerfield Management, adding an estimated $18M. The largest seller was Novo Holdings A/S, cutting an estimated $13.2M.
- 55 institutional investors held Inozyme Pharma (INZY) as of Q1 2021, up from 54 in Q4 2020.
- Funds reported $379M of Inozyme Pharma stock for Q1 2021, up 0.11% quarter-over-quarter.
- 6 funds opened new Inozyme Pharma positions in Q1 2021 and 5 closed out, a net change of +1 holder.
- The largest Inozyme Pharma buyer in Q1 2021 was Deerfield Management, an estimated $18M added.
- The largest Inozyme Pharma seller in Q1 2021 was Novo Holdings A/S, an estimated $13.2M sold.
Based on aggregated 13F filings for Q1 2021.